In yesterday’s Wall Street session, Novo Nordisk ADR (NYSE:NVO) shares traded at $123.05, down -0.78% from the previous session.
NVO stock price is now -3.22% away from the 50-day moving average and 16.14% away from the 200-day moving average. The market capitalization of the company currently stands at $410.79B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $163, BMO Capital Markets recently initiated with Outperform rating for Novo Nordisk ADR (NYSE: NVO). On January 23, 2024, Morgan Stanley recently initiated its ‘Overweight’ rating on the stock quoting a target price of $120, while ‘UBS’ rates the stock as ‘Neutral’
A total of 0.00% of the company’s stock is owned by insiders.
During the past 12 months, Novo Nordisk ADR has had a low of $75.56 and a high of $138.28. As of last week, the company has a debt-to-equity ratio of 0.27, a current ratio of 0.70, and a quick ratio of 0.50.
The net profit margin was 36.56% and return on equity was 99.99% for NVO. The company reported revenue of $9.51 billion for the quarter, compared to $7.69 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 23.73 percent.
Novo Nordisk ADR(NVO) Company Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
